

“E” to “Bath Salts”: Synthetic Psychostimulants and Hallucinogens

Silas W. Smith, MD, FACEP

CSAM. Addiction Medicine Review Course 2014. September 6, 2014

REFERENCES

Presentation

- Bialer PA. Designer drugs in the general hospital. *Psychiat Clin N Am*. 2002;25:231-43.
- Babu KM, McCurdy CR, Boyer EW. Opioid receptors and legal highs: Salvia divinorum and Kratom. *Clin Toxicol (Phila)*. 2008;46:146-52.
- Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (*Mitragynia speciosa korth*). *Addiction*. 2008;103:1048-50.
- Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT_{2A} receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. *Mol Pharmacol*. 2006;70:1956-64.
- Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase I hydroxylated metabolites of the K₂ synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. *PLoS One*. 2011;6:e21917.
- Center for Substance Abuse Treatment, SAMHSA. Inhalants. *Substance Abuse Treatment Advisory*. March 2003;3(1):1-8.
- Chambers JJ, Kurrasch-Orbaugh DM, Parker MA, Nichols DE. Enantiospecific Synthesis and Pharmacological Evaluation of a Series of Super-Potent, Conformationally Restricted 5-HT_{2A/2C} Receptor Agonists. *J Med Chem*. 2001;44:1003-10.
- Cohen BMZ, Butler R. BZP-party pills: A review of research on benzylpiperazine as a recreational drug. *Int J Drug Policy*. 2011;22:95-101.
- Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. *J Pharmacol Exp Ther*. 1992;260:201-209.
- Daly M, Simonson P. Street Drug Trends Survey 2011: The ketamine zone. *Druglink*. 2011;November/December:6-9.
- D'Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M. Nicotine Fails to Attenuate Ketamine-Induced Cognitive Deficits and Negative and Positive Symptoms in Humans: Implications for Schizophrenia. *Biol Psychiatry*. 2012 Jun 18 [Epub ahead of print].
- EMCDDA. GHB and its precursor GBL: an emerging trend case study. Thematic papers, European Monitoring Centre for Drugs and Drug Addiction. Lisbon; 2008. Available at: <http://www.emcdda.europa.eu/publications/thematic-papers/ghb> [accessed 14 Aug 2014].
- Fantegrossi WE, Murnane KS, Reissig CJ. The behavioral pharmacology of hallucinogens. *Biochem Pharmacol*. 2008;75:17-33.
- Franklin PH, Murray TF. High affinity [³H]dextrorphan binding in rat brain is localized to a noncompetitive antagonist site of the activated N-methyl-D-aspartate receptor-cation channel. *Mol Pharmacol*. 1992;41:134-46.
- Gee P, Gilbert M, Richardson S, Moore G, Paterson S, Graham P. Toxicity from the recreational use of 1-benzylpiperazine. *Clin Toxicol (Phila)*. 2008;46:802-7.
- Global Drug Survey. Facts and Figures. Published online at <http://www.globaldrugsurvey.com/facts-figures/> [accessed 27 July 2014].
- Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. A survey of synthetic cannabinoid consumption by current cannabis users. *Subst Abus*. 2014;35:184-9.

“E” to “Bath Salts”: Synthetic Psychostimulants and Hallucinogens

Silas W. Smith, MD, FACEP

CSAM. Addiction Medicine Review Course 2014. September 6, 2014

- Halpern JH, Sherwood AR, Hudson JI, Yurgelun-Todd D, Pope HG Jr. Psychological and cognitive effects of long-term peyote use among Native Americans. *Biol Psychiatry*. 2005;58:624-31.
- Hofmann A, Frey A, Ott H, Petrzilka T, Troxler F. Konstitutionsaufklärung und synthese von psilocybin. *Experientia*. 1958;14:107-109.
- Hsu CK, Chen YQ, Lung VZ, His SC, Lo HC, Shyu HY. Myelopathy and polyneuropathy caused by nitrous oxide toxicity: a case report. *Am J Emerg Med*. 2012;30:1016.e3-6.
- Jansen KLR. A review of the nonmedical use of ketamine: use, users and consequences. *J Psychoactive Drugs*. 2000;32:419-33.
- JHP Pharmaceuticals LLC. Prescribing Information. KETALAR - ketamine hydrochloride injection. Rochester, MI: JHP Pharmaceuticals, LLC, 2012.
- Johnston LD, O'Malley PM, Miech RA, Bachman JG, Schulenberg JE. Monitoring the Future. National results on drug use: 1975-2013: Overview, Key Findings on Adolescent Drug Use. Ann Arbor, MI: Institute for Social Research, The University of Michigan, 2014.
- Kapp FG, Maurer HH, Auwärter V, Winkelmann M, Hermanns-Clausen M. Intrahepatic Cholestasis Following Abuse of Powdered Kratom (*Mitragyna speciosa*). *J Med Toxicol*. 2011;7:227-31.
- Kendler KS, Jacobson KC, Prescott CA, Neale MC. Specificity of genetic and environmental risk factors for use and abuse/dependence of cannabis, cocaine, hallucinogens, sedatives, stimulants, and opiates in male twins. *Am J Psychiatry*. 2003;160:687-95.
- Lessenger JE, Feinberg SD. Abuse of prescription and over-the-counter medications. *J Am Board Fam Med*. 2008;21:45-54
- Leung KS, Cottler LB. Ecstasy and other club drugs: a review of recent epidemiologic studies. *Curr Opin Psychiatry*. 2008;21:234-41.
- Licht CL, Christoffersen M, Okholm M, Damgaard L, Fink-Jensen A, Knudsen GM, Erritzoe D. Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases. *Hum Psychopharmacol*. 2012;27:352-63.
- Lin JC, Bangs N, Lee HS, Kydd RR, Russell BR. Determining the subjective and physiological effects of BZP on human females. *Psychopharmacology (Berl)*. 2009;207:439-46.
- Martín-Santos R, Torrens M, Poudevida S, Langohr K, Cuyás E, Pacifici R, Farré M, Pichini S, de la Torre R. 5-HTTLPR polymorphism, mood disorders and MDMA use in a 3-year follow-up study. *Addict Biol*. 2010;15:15-22.
- McWhirter L, Morris S. A case report of inpatient detoxification after kratom (*Mitragyna speciosa*) dependence. *Eur Addict Res*. 2010;16:229-31.
- Ng SH, Tse ML, Ng HW, Lau FL. Emergency department presentation of ketamine abusers in Hong Kong: a review of 233 cases. *Hong Kong Med J*. 2010;16:6-11.
- Nikolaou P, Papoutsis I, Stefanidou M, Spiliopoulou C, Athanaselis S. 2C-I-NBOMe, an "N-bomb" that kills with "Smiles". Toxicological and legislative aspects. *Drug Chem Toxicol*. 2014 May 1 (epub ahead of print).
- Parker MA, Marona-Lewicka D, Lucaites VL, Nelson DL, Nichols DE. A novel (benzodifuranyl)aminoalkane with extremely potent activity at the 5-HT_{2A} receptor. *J*

“E” to “Bath Salts”: Synthetic Psychostimulants and Hallucinogens

Silas W. Smith, MD, FACEP

CSAM. Addiction Medicine Review Course 2014. September 6, 2014

- Med Chem. 1998;41:5148-9.
- Parrott AC. MDMA and temperature: a review of the thermal effects of 'Ecstasy' in humans. *Drug Alcohol Depend.* 2012;121:1-9.
- Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. *Addict Biol.* 2002;7:357-64.
- Pendergraft WF 3rd, Herlitz LC, Thornley-Brown D, Rosner M, Niles JL. Nephrotoxic Effects of Common and Emerging Drugs of Abuse. *Clin J Am Soc Nephrol.* 2014 Jul 17.
- Persson J. Wherefore ketamine? *Curr Opin Anaesthesiol.* 2010;23:455-60.
- Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. *J Med Toxicol.* 2012;8:33-42.
- Romanelli F, Smith KM. Dextromethorphan abuse: Clinical effects and management. *Pharmacy Today.* 2009;15:48-55.
- Sadzot B, Baraban JM, Glennon RA, Lyon RA, Leonhardt S, Jan CR, Titeler M. Hallucinogenic drug interactions at human brain 5-HT₂ receptors: implications for treating LSD-induced hallucinogenesis. *Psychopharmacology (Berl).* 1989;98:495-9.
- Sanders-Bush E, Burris KD, Knoth K. Lysergic acid diethylamide and 2,5-dimethoxy-4-methylamphetamine are partial agonists at serotonin receptors linked to phosphoinositide hydrolysis. *J Pharmacol Exp Ther.* 1988;246:924-8.
- Sarkar S, Schmued L. Neurotoxicity of ecstasy (MDMA): an overview. *Curr Pharm Biotechnol.* 2010;11:460-9.
- Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Mégarbane B. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. *Clin Toxicol (Phila).* 2012;50:458-70.
- Sear JW. Ketamine hepato-toxicity in chronic pain management: another example of unexpected toxicity or a predicted result from previous clinical and pre-clinical data? *Pain.* 2011;152:1946-7.
- Steinkellner T, Freissmuth M, Sitte HH, Montgomery T. The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine. *Biol Chem.* 2011;392:103-15.
- Stone AL, Storr CL, Anthony JC. Evidence for a hallucinogen dependence syndrome developing soon after onset of hallucinogen use during adolescence. *Int J Methods Psychiatr Res.* 2006;153:116-30.
- Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.
- Substance Abuse and Mental Health Services Administration. The Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.
- Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2002-2012. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-71, HHS Publication No. (SMA) 14-4850. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2014.

“E” to “Bath Salts”: Synthetic Psychostimulants and Hallucinogens

Silas W. Smith, MD, FACEP

CSAM. Addiction Medicine Review Course 2014. September 6, 2014

- Tang MH, Ching CK, Tsui MS, Chu FK, Mak TW. Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. *Clin Toxicol (Phila)*. 2014;52:561-5.
- Thorlacius K, Borna C, Personne M. Bromo-dragon fly--life-threatening drug. Can cause tissue necrosis as demonstrated by the first described case [Swedish]. *Lakartidningen*. 2008;105:1199-2000.
- US Drug Enforcement Administration, Office of Diversion Control. National Forensic Laboratory Information System: 2013 Midyear Report. Springfield, VA: US Drug Enforcement Administration, 2014.
- US Food and Drug Administration (FDA). Background information prepared by the Food and Drug Administration (FDA) for the Meeting of the Drug Safety and Risk Management Advisory Committee, September 14, 2010. Available from: <http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/drugsafetyandriskmanagementadvisorycommittee/ucm224446.pdf> [accessed 14 Aug 2014].
- Udesky JO, Spence NZ, Achiel R, Lee C, Flood P. The role of nicotinic inhibition in ketamine-induced behavior. *Anesth Analg*. 2005;101:407-11.
- United Nations Office on Drugs and Crime (UNODC). World drug report 2014. Sales No. E.14.XI.7. New York: United Nations, 2014.
- Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of Spice products (synthetic cannabinoids). *Drug Alcohol Depend*. 2012;120:238-41.
- van Holst RJ, Schilt T. Drug-related decrease in neuropsychological functions of abstinent drug users. *Curr Drug Abuse Rev*. 2011;4:42-56.
- Wilcox HC, Wagner FA, Anthony JC. Exposure opportunity as a mechanism linking youth marijuana use to hallucinogen use. *Drug Alcohol Depend*. 2002;66:127-35.
- Winstock AR, Mitcheson L. New recreational drugs and the primary care approach to patients who use them. *BMJ*. 2012 Feb 15;344:e288. doi: 10.1136/bmj.e288.
- Winter JC. Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. *Psychopharmacology (Berl)*. 2009;203(2):251-63.
- Wood DM, Looker JJ, Shaikh L, Button J, Puchnarewicz M, Davies S, Lidder S, Ramsey J, Holt DW, Dargan PI. Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragonFLY. *J Med Toxicol*. 2009;5:226-29.
- Wood D, Cottrell A, Baker SC, Southgate J, Harris M, Fulford S, Woodhouse C, Gillatt D. Recreational ketamine: from pleasure to pain. *BJU Intern*. 2011;107:1881-1884.
- Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". *Dtsch Arztebl Int*. 2009 Jul;106:464-67.

“E” to “Bath Salts”: Synthetic Psychostimulants and Hallucinogens

Silas W. Smith, MD, FACEP

CSAM. Addiction Medicine Review Course 2014. September 6, 2014

Review resources

Babu KM, McCurdy CR, Boyer EW. Opioid receptors and legal highs: Salvia divinorum and Kratom. *Clin Toxicol (Phila)*. 2008;46:146-52.

Boyer EW. Dextromethorphan abuse. *Pediatr Emerg Care*. 2004;20:858-63.

Cohen BMZ, Butler R. BZP-party pills: A review of research on benzylpiperazine as a recreational drug. *Int J Drug Policy*. 2011;22:95-101.

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Drug profiles [various]. Available from: <http://www.emcdda.europa.eu/drug-profiles> [accessed 2014 July 25].

German CL, Fleckenstein AE, Hanson GR. Bath salts and synthetic cathinones: an emerging designer drug phenomenon. *Life Sci*. 2014;97:2-8.

Hill SL, Thomas SHL. Clinical toxicology of newer recreational drugs. *Clin Toxicol (Phila)*. 2011;49:705-719.

Karila L, Reynaud M. GHB and synthetic cathinones: clinical effects and potential consequences. *Drug Test Analysis* 2011;3:552–559.

Musselman ME, Hampton JP. "Not for human consumption": a review of emerging designer drugs. *Pharmacotherapy*. 2014;34:745-57.

Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. *Emerg Med Clin North Am*. 2014;32:1-28.

US Drug Enforcement Administration, Office of Diversion Control. Special Report: Synthetic Cannabinoids and Synthetic Cathinones Reported in NFLIS, 2010–2013. Springfield, VA: US Drug Enforcement Administration, 2014.